Bassam Janji

Latest publications

Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.

  • Tumor Immunotherapy and Microenvironment
November 01, 2020
2020 Nov. Autophagy.(11):2110-2111. Epub 2020 Sep 5.
By:
  • Janji B
  • Hasmim M
  • Parpal S
  • De Milito A
  • Berchem G
  • Noman MZ.

The 'Holy Grail' in immuno-oncology: AC BioScience SA is aiming to potentiate anti-PD-1 therapy efficacy through tumor cell conditioning strategy.

  • Tumor Immunotherapy and Microenvironment
October 28, 2020
2020 Oct. Chimia.74(10):771-775.
By:
  • Schlapfer A
  • Auclair C
  • Janji B
  • Karam M
  • Zaeem Noman M.

Firing up the cold tumors by targeting Vps34.

  • Tumor Immunotherapy and Microenvironment
August 31, 2020
2020 Aug. OncoImmunology.9(1):1809936.
By:
  • Janji B
  • Hasmim M
  • Parpal S
  • Berchem G
  • Noman MZ.

Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC/PKC-EZR (ezrin) pathway.

  • Tumor Immunotherapy and Microenvironment
  • Multiomics Data Science
  • Luxembourg Center of Neuropathology
August 01, 2020
2020 Aug. Autophagy.16(8):1436-1452. Epub 2019 Nov 27.
By:
  • Qureshi-Baig K
  • Kuhn D
  • Viry E
  • Pozdeev VI
  • Schmitz M
  • Rodriguez F
  • Ullmann P
  • Koncina E
  • Nurmik M
  • Frasquilho S
  • Nazarov PV
  • Zuegel N
  • Boulmont M
  • Karapetyan Y
  • Antunes L
  • Val D
  • Mittelbronn M
  • Janji B
  • Haan S
  • Letellier E.

The emerging impact of autophagy on the antitumor immune response. In Autophagy in immune response: Impact on cancer immunotherapy. 1st ed. (Book Chapter)

  • Tumor Immunotherapy and Microenvironment
May 11, 2020
2020 May. Chouaib S, ed. London: Academic Press, 2020. p.109-117. (Sensitizing Agent-Canc Resistant-Cell Mediated Immtherap, Vol.1). ISBN 978-0-12-819609-0.
By:
  • Hasmim M
  • Xiao M
  • Viry E
  • Noman MZ
  • Duhem C
  • Berchem G
  • Janji B.

Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.

  • Tumor Immunotherapy and Microenvironment
May 01, 2020
2020 May. Sci Adv.6(18):eaax7881.
By:
  • Noman MZ
  • Parpal S
  • Van Moer K
  • Xiao M
  • Yu Y
  • Viklund J
  • De Milito A
  • Hasmim M
  • Andersson M
  • Amaravadi RK
  • Martinsson J
  • Berchem G
  • Janji B.

Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges.

  • Tumor Immunotherapy and Microenvironment
September 14, 2019
2019 Sep. Cells.8(9).
By:
  • Noman MZ
  • Hasmim M
  • Lequeux A
  • Xiao M
  • Duhem C
  • Chouaib S
  • Berchem G
  • Janji B.

Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints.

  • Tumor Immunotherapy and Microenvironment
August 28, 2019
2019 Aug. Cancer Lett.458:13-20. Epub 2019 May 25.
By:
  • Lequeux A
  • Noman MZ
  • Xiao M
  • Sauvage D
  • Van Moer K
  • Viry E
  • Bocci I
  • Hasmim M
  • Bosseler M
  • Berchem G
  • Janji B.

The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment.

  • Immuno-Pharmacology and Interactomics
  • Tumor Immunotherapy and Microenvironment
  • NORLUX Neuro-Oncology Laboratory
June 18, 2019
2019 Jun. Cells.8(6).
By:
  • Reynders N
  • Abboud D
  • Baragli A
  • Noman MZ
  • Rogister B
  • Niclou SP
  • Heveker N
  • Janji B
  • Hanson J
  • Szpakowska M
  • Chevigne A.

Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.

  • Tumor Immunotherapy and Microenvironment
  • NORLUX Neuro-Oncology Laboratory
April 01, 2019
2019 Apr. Int J Cancer.144(7):1735-1745. Epub 2018 Dec 11.
By:
  • Johannessen TC
  • Hasan-Olive MM
  • Zhu H
  • Denisova O
  • Grudic A
  • Latif MA
  • Saed H
  • Varughese JK
  • Rosland GV
  • Yang N
  • Sundstrom T
  • Nordal A
  • Tronstad KJ
  • Wang J
  • Lund-Johansen M
  • Simonsen A
  • Janji B
  • Westermarck J
  • Bjerkvig R
  • Prestegarden L.

Actin cytoskeleton remodeling drives breast cancer cell escape from natural killer-mediated cytotoxicity.

  • Cytoskeleton and Cancer Progression
  • Platform National Cytometry
  • NORLUX Neuro-Oncology Laboratory
  • Tumor Immunotherapy and Microenvironment
October 01, 2018
2018 Oct. Cancer Res.78(19):5631-5643. Epub 2018 Aug 13.
By:
  • Al Absi A
  • Wurzer H
  • Guerin C
  • Hoffmann C
  • Moreau F
  • Mao X
  • Brown-Clay J
  • Petrolli R
  • Casellas CP
  • Dieterle M
  • Thiery JP
  • Chouaib S
  • Berchem G
  • Janji B
  • Thomas C.

Driving cytotoxic natural killer cells into melanoma: If CCL5 plays the music, autophagy calls the shots.

  • Tumor Immunotherapy and Microenvironment
  • Immuno-Pharmacology and Interactomics
  • Allergy and Clinical Immunology
September 11, 2018
2018 Sep. Crit Rev Oncog.23(5-6):321-332.
By:
  • Xiao M
  • Noman MZ
  • Menard L
  • Chevigne A
  • Szpakowska M
  • Bosseler M
  • Ollert M
  • Berchem G
  • Janji B.

Hypoxia promotes breast cancer cell invasion through HIF-1α-mediated up-regulation of the invadopodial actin bundling protein CSRP2.

  • Cytoskeleton and Cancer Progression
  • Tumor Immunotherapy and Microenvironment
July 05, 2018
2018 Jul. Sci Rep.8(1):10191.
By:
  • Hoffmann C
  • Mao X
  • Brown-Clay J
  • Moreau F
  • Al Absi A
  • Wurzer H
  • Sousa B
  • Schmitt F
  • Berchem G
  • Janji B
  • Thomas C.

High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia.

  • Tumor Stroma Interactions
  • Tumor Immunotherapy and Microenvironment
May 24, 2018
2018 May. OncoImmunology.7(8):e1465167.
By:
  • Wierz M
  • Janji B
  • Berchem G
  • Moussay E
  • Paggetti J.

Inhibition of HIF1alpha-dependent upregulation of Phospho-l-Plastin resensitizes multiple myeloma cells to frontline therapy.

  • Tumor Immunotherapy and Microenvironment
  • Computational Biomedicine
  • Laboratory of Oncolytic-Virus-Immuno-Therapeutics
May 23, 2018
2018 May. Int J Mol Sci.19(6):1551.
By:
  • Bosseler M
  • Marani V
  • Broukou A
  • Lequeux A
  • Kaoma T
  • Schlesser V
  • Francois JH
  • Palissot V
  • Berchem GJ
  • Aouali N
  • Janji B.

Targeting autophagy in the tumor microenvironment: New challenges and opportunities for regulating tumor immunity.

  • Tumor Immunotherapy and Microenvironment
April 25, 2018
2018 Apr. Front Immunol.9:887.
By:
  • Janji B
  • Berchem G
  • Chouaib S.

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target.

  • Tumor Immunotherapy and Microenvironment
  • Tumor Stroma Interactions
April 25, 2018
2018 Apr. OncoImmunology.7(8):e1452583.
By:
  • Noman MZ
  • Paggetti J
  • Moussay E
  • Berchem G
  • Janji B.

Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.

  • Tumor Stroma Interactions
  • Platform National Cytometry
  • Tumor Immunotherapy and Microenvironment
  • NORLUX Neuro-Oncology Laboratory
  • Allergy and Clinical Immunology
April 05, 2018
2018 Apr. Blood.131(14):1617-1621. Epub 2018 Feb 13.
By:
  • Wierz M
  • Pierson S
  • Guyonnet L
  • Viry E
  • Lequeux A
  • Oudin A
  • Niclou SP
  • Ollert M
  • Berchem G
  • Janji B
  • Guerin C
  • Paggetti J
  • Moussay E.

Targeting autophagy blocks melanoma growth by bringing natural killer cells to the tumor battlefield.

  • Tumor Immunotherapy and Microenvironment
March 11, 2018
2018 Mar. Autophagy.14(4):730-732. Epub 2018 Mar 11.
By:
  • Noman MZ
  • Berchem G
  • Janji B.

CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.

  • Tumor Immunotherapy and Microenvironment
  • Computational Biomedicine
February 15, 2018
2018 Feb. OncoImmunology.7(4):e1345415.
By:
  • Noman MZ
  • Van Moer K
  • Marani V
  • Gemmill RM
  • Tranchevent LC
  • Azuaje F
  • Muller A
  • Chouaib S
  • Thiery JP
  • Berchem G
  • Janji B.